Search clinical trials for: tiotropium-bromide

Total 906 results

Boehringer Ingelheim

Completed

An Efficacy and Safety Evaluation of Tiotropium add-on Therapy in Patients With Severe Persistent Asthma

Asthma

Germany, Denmark, Netherlands
Laval University
Boehringer Ingelheim

Completed

Effects of Tiotropium on Walking Capacity in Patients With COPD

Chronic Obstructive Pulmonary Disease

Canada
Boehringer Ingelheim

Completed

Acute Bronchodilator Response of a Single Dose of Atrovent or Berotec on Top of Pharmacodynamic Steady State of Spiriva

Pulmonary Disease, Chronic Obstructive

Netherlands
National Institute of Respiratory Diseases, Mexico

Completed

Efficacy and Safety of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass Exposure (EMERALD2)

COPD

Mexico
3M

Completed

Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With A Reference Product

Healthy

United Kingdom
Theron Pharmaceuticals, Inc.

Completed

Multiple Ascending Dose Study of TRN-157 in Stable Mild and Moderate Asthmatics

Asthma

United States
Boehringer Ingelheim

Completed

Spiriva® Assessment of FEV1 (SAFE)

Pulmonary Disease, Chronic Obstructive

Canada
AstraZeneca

Completed

A Single-dose Study to Investigate the Effects of 3 Different Doses of Inhaled AZD2115 in COPD Patients

COPD

Poland, Sweden
National Jewish Health
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Examining the Link Between Obesity, Inflammation, and Response to Asthma Medications

Obesity | Asthma

United States
Brigham and Women's Hospital
Massachusetts General Hospital; Baim Institute for Clinical Research

Terminated

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations (GABLE)

Asthma

United States
Botanix Pharmaceuticals

Completed

Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301) (Cardigan I)

Axillary Hyperhidrosis

United States
Boehringer Ingelheim

Completed

Efficacy and Safety of Free Combination of Tiotropium + Formoterol Compared to Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Novartis Pharmaceuticals

Completed

Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD

COPD

Germany, Spain, United Kingdom, Italy
National University of Malaysia

Completed

Tiotropium Respimat Administration With and Without Aerochamber Disease (COPD)

Chronic Obstructive Pulmonary Disease

Malaysia
Boehringer Ingelheim

Completed

Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients

Pulmonary Disease, Chronic Obstructive

Belgium, Canada, Netherlands, Germany
Boehringer Ingelheim

Completed

Dose Finding Study in COPD

Pulmonary Disease, Chronic Obstructive

Netherlands, Belgium, United States
University of Crete

Completed

Tiotropium Respimat Versus HandiHaler on SaO2 and Sleep in COPD Patients

Chronic Obstructive Pulmonary Disease
Novartis Pharmaceuticals

Completed

Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

Colombia, India, Korea, Republic of, Poland, Croatia, Estonia, Hungary, United Kingdom, Israel, Latvia, Turkey, Argentina, Panama, Mexico, Russian Federation, Serbia, Slovenia
National Institute of Respiratory Diseases, Mexico

Completed

Efficacy in Walked Distance of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass (EMERALD) (EMERAL)

COPD

Mexico
Boehringer Ingelheim

Completed

Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

High Dose Trial in COPD

Pulmonary Disease, Chronic Obstructive

United States
Yonsei University

Not yet recruiting

Effects of Tiotropium/Olodaterol on Cardio-pulmonary Exercise Capacity in Patients With Hyperinflated Chronic Obstructive Pulmonary Disease [ACHIEVE]

Chronic Obstructive Pulmonary Disease

Korea, Republic of
Boehringer Ingelheim

Completed

Effect of Tiotropium on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Tiotropium / Respimat One-Year Study

Pulmonary Disease, Chronic Obstructive

Austria, Canada, Spain, United States, Finland, Italy, Russian Federation, United Kingdom, New Zealand, Australia, France, Greece, Ireland, Netherlands, South Africa
Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca

Completed

The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease (LaCrossE)

Chronic Obstructive Pulmonary Disease

Sweden
Boehringer Ingelheim

Completed

A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale

Pulmonary Disease, Chronic Obstructive

United States, Germany
Boehringer Ingelheim

Completed

Comparison of Tiotropium Inhalation Capsules and Oxitropium Metered Dose Inhalator (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma

Pulmonary Disease, Chronic Obstructive | Asthma

Netherlands, Germany, Belgium, France, Canada, Italy, South Africa, Denmark
GlaxoSmithKline

Completed

Safety Study Using GSK573719 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)

Pulmonary Disease, Chronic Obstructive

United States, Belgium, Canada, Czech Republic, Denmark, Finland, Germany, South Africa, Spain, United Kingdom
Boehringer Ingelheim

Completed

Japan Long-term Safety for Tiotropium Plus Olodaterol

Pulmonary Disease, Chronic Obstructive

Japan
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)

Asthma

United States, Australia, Canada, Denmark, Germany, Italy, Japan, Netherlands, New Zealand, Russian Federation, Serbia, South Africa, Turkey, Ukraine, United Kingdom
Boehringer Ingelheim

Completed

12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea Scales

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Terminated

Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Pharmacokinetic Study in Elderly Patients With Chronic Obstructive Bronchitis (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD

Pulmonary Disease, Chronic Obstructive

United States, Canada
University of Dundee
Tenovus Scotland

Completed

Ultra-long Acting Bronchodilator Therapy in Asthmatics (MAN02)

Asthma

United Kingdom
Queen's University
Boehringer Ingelheim

Completed

Effects of Dual Bronchodilator Treatment on Cardiopulmonary Interactions in COPD

Chronic Obstructive Pulmonary Disease

Canada
Boehringer Ingelheim

Completed

Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, India, Ireland, Italy, Japan, Korea, Republic of, Latv... and more
GlaxoSmithKline

Completed

Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany
Novartis Pharmaceuticals

Completed

Effect of Indacaterol on Inspiratory Capacity (IC)

Chronic Obstructive Pulmonary Disease

Germany
Boehringer Ingelheim

Completed

Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)

Pulmonary Disease, Chronic Obstructive

United States, Australia, Austria, Canada, Germany, Greece, New Zealand, Norway, Slovakia, South Africa, Sweden
ThomasTruncale
Boehringer Ingelheim

Completed

The Effects of Tiotropium on the Cough Reflex in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease | Chronic Bronchitis

United States
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)

Asthma

United States, Australia, Canada, Denmark, Germany, Italy, Japan, Netherlands, Russian Federation, Serbia, South Africa, Turkey, Ukraine, United Kingdom
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma

Asthma

Japan
Boehringer Ingelheim

Completed

Tiotropium / Respimat One-Year Study

Pulmonary Disease, Chronic Obstructive

Germany, Canada, Spain, Russian Federation, United States, Belgium, France, Greece, Sweden, Norway, Turkey, Australia, Netherlands, United Kingdom
Boehringer Ingelheim

Completed

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Belgium, Netherlands
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Terminated

Bronchodilators and Respiratory Mechanics in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

Italy

3

Subscribe